Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
Domain	PID_Shc-like	SHC2 SHC3	1.60e-05	4	31	2	IPR006019
Domain	-	PRKD3 PPP4R3B PLEKHA2 SHC2 SHC3	4.25e-04	391	31	5	2.30.29.30
Domain	PH_dom-like	PRKD3 PPP4R3B PLEKHA2 SHC2 SHC3	6.28e-04	426	31	5	IPR011993
Domain	PID	SHC2 SHC3	9.81e-04	28	31	2	PF00640
Domain	PID	SHC2 SHC3	1.28e-03	32	31	2	PS01179
Domain	PTB	SHC2 SHC3	2.00e-03	40	31	2	SM00462
Domain	PTB/PI_dom	SHC2 SHC3	2.10e-03	41	31	2	IPR006020
Domain	UBA	SNRK USP13	2.42e-03	44	31	2	IPR015940
Domain	Ser/Thr_kinase_AS	TAOK2 PRKD3 SNRK MAPK1	2.75e-03	357	31	4	IPR008271
Domain	UBA	SNRK USP13	2.75e-03	47	31	2	PS50030
Domain	S_TKc	TAOK2 PRKD3 SNRK MAPK1	2.80e-03	359	31	4	SM00220
Domain	PROTEIN_KINASE_ST	TAOK2 PRKD3 SNRK MAPK1	2.89e-03	362	31	4	PS00108
Domain	Protein_kinase_ATP_BS	TAOK2 PRKD3 SNRK MAPK1	3.40e-03	379	31	4	IPR017441
Domain	Pkinase	TAOK2 PRKD3 SNRK MAPK1	3.47e-03	381	31	4	PF00069
Domain	CH	PARVG SYNE2	5.20e-03	65	31	2	SM00033
Domain	CH	PARVG SYNE2	6.00e-03	70	31	2	PF00307
Domain	-	PARVG SYNE2	6.17e-03	71	31	2	1.10.418.10
Domain	CH	PARVG SYNE2	6.51e-03	73	31	2	PS50021
Domain	PROTEIN_KINASE_ATP	TAOK2 PRKD3 SNRK MAPK1	6.70e-03	459	31	4	PS00107
Domain	CH-domain	PARVG SYNE2	6.86e-03	75	31	2	IPR001715
Domain	Prot_kinase_dom	TAOK2 PRKD3 SNRK MAPK1	8.34e-03	489	31	4	IPR000719
Domain	PROTEIN_KINASE_DOM	TAOK2 PRKD3 SNRK MAPK1	8.58e-03	493	31	4	PS50011
Domain	Kinase-like_dom	TAOK2 PRKD3 SNRK MAPK1	1.19e-02	542	31	4	IPR011009
Domain	SH2	SHC2 SHC3	1.22e-02	101	31	2	PF00017
Domain	SH2	SHC2 SHC3	1.43e-02	110	31	2	SM00252
Domain	SH2	SHC2 SHC3	1.45e-02	111	31	2	PS50001
Domain	SH2	SHC2 SHC3	1.48e-02	112	31	2	IPR000980
Domain	-	SHC2 SHC3	1.48e-02	112	31	2	3.30.505.10
Pathway	REACTOME_SIGNALLING_TO_ERKS	MAPK1 SHC2 SHC3	1.10e-05	26	24	3	MM14716
Pathway	REACTOME_SIGNALLING_TO_ERKS	MAPK1 SHC2 SHC3	2.51e-05	34	24	3	M13881
Pathway	WP_ANGIOPOIETINLIKE_PROTEIN_8_REGULATORY_PATHWAY	MAPK1 THRA SHC2 SHC3	6.75e-05	132	24	4	M39338
Pathway	WP_BREAST_CANCER_PATHWAY	MAPK1 SHC2 LEF1 SHC3	1.23e-04	154	24	4	M39739
Pathway	KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_PATHWAY_ADAPTOR_PROTEINS	SHC2 SHC3	1.24e-04	10	24	2	M47930
Pathway	PID_TRKR_PATHWAY	MAPK1 SHC2 SHC3	1.46e-04	61	24	3	M187
Pathway	REACTOME_SIGNALING_BY_NTRK1_TRKA	MAPK1 SHC2 SHC3	1.61e-04	63	24	3	MM14714
Pathway	KEGG_GLIOMA	MAPK1 SHC2 SHC3	1.77e-04	65	24	3	M1835
Pathway	REACTOME_SIGNALLING_TO_RAS	SHC2 SHC3	1.81e-04	12	24	2	MM14657
Pathway	KEGG_CHRONIC_MYELOID_LEUKEMIA	MAPK1 SHC2 SHC3	2.49e-04	73	24	3	M321
Pathway	REACTOME_SIGNALING_BY_NTRKS	MAPK1 SHC2 SHC3	2.70e-04	75	24	3	MM14652
Pathway	WP_FOCAL_ADHESION	MAPK1 SHC2 PARVG SHC3	3.28e-04	199	24	4	M39402
Pathway	KEGG_FOCAL_ADHESION	MAPK1 SHC2 PARVG SHC3	3.28e-04	199	24	4	M7253
Pathway	WP_EGFR_TYROSINE_KINASE_INHIBITOR_RESISTANCE	MAPK1 SHC2 SHC3	3.77e-04	84	24	3	M39839
Pathway	KEGG_ERBB_SIGNALING_PATHWAY	MAPK1 SHC2 SHC3	4.18e-04	87	24	3	M12467
Pathway	WP_ERBB_SIGNALING	MAPK1 SHC2 SHC3	4.93e-04	92	24	3	M39715
Pathway	REACTOME_SIGNALLING_TO_RAS	SHC2 SHC3	5.18e-04	20	24	2	M12256
Pathway	PID_PRL_SIGNALING_EVENTS_PATHWAY	ATF5 MAPK1	6.88e-04	23	24	2	M11
Pathway	PID_VEGFR1_PATHWAY	MAPK1 SHC2	8.81e-04	26	24	2	M226
Pathway	WP_FGFR3_SIGNALING_IN_CHONDROCYTE_PROLIFERATION_AND_TERMINAL_DIFFERENTIATION	MAPK1 THRA	9.50e-04	27	24	2	M39838
Pathway	KEGG_THYROID_CANCER	MAPK1 LEF1	1.10e-03	29	24	2	M523
Pathway	KEGG_NEUROTROPHIN_SIGNALING_PATHWAY	MAPK1 SHC2 SHC3	1.23e-03	126	24	3	M16763
Pubmed	Tat protein from HIV-1 activates MAP kinase in granular neurons and glial cells from rat cerebellum.	MAPK1 SHC2 SHC3	2.24e-08	7	31	3	9325171
Pubmed	HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway.	MAPK1 SHC2 SHC3	1.40e-07	12	31	3	16436505
Pubmed	A family of Shc related proteins with conserved PTB, CH1 and SH2 regions.	SHC2 SHC3	7.69e-07	2	31	2	8760305
Pubmed	The variant Polycomb Repressor Complex 1 component PCGF1 interacts with a pluripotency sub-network that includes DPPA4, a regulator of embryogenesis.	SUGP1 NAP1L4 TUBGCP2 ATG13 PCLO PTCD3	1.21e-06	396	31	6	26687479
Pubmed	Nerve growth factor signaling, neuroprotection, and neural repair.	MAPK1 SHC2 SHC3	1.64e-06	26	31	3	11520933
Pubmed	Nesprin-2-dependent ERK1/2 compartmentalisation regulates the DNA damage response in vascular smooth muscle cell ageing.	MAPK1 SYNE2	2.31e-06	3	31	2	25744025
Pubmed	TAO (thousand-and-one amino acid) protein kinases mediate signaling from carbachol to p38 mitogen-activated protein kinase and ternary complex factors.	TAOK2 MAPK1	2.31e-06	3	31	2	12665513
Pubmed	Evolution of Shc functions from nematode to human.	SHC2 SHC3	2.31e-06	3	31	2	11088019
Pubmed	De-phosphorylation of TRalpha-1 by p44/42 MAPK inhibition enhances T(3)-mediated GLUT5 gene expression in the intestinal cell line Caco-2 cells.	MAPK1 THRA	2.31e-06	3	31	2	17577579
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	SUGP1 NAP1L4 PPP4R3B AARS1 MAPK1 TUBGCP2 IK IKZF5	4.11e-06	1103	31	8	34189442
Pubmed	Novel nuclear nesprin-2 variants tether active extracellular signal-regulated MAPK1 and MAPK2 at promyelocytic leukemia protein nuclear bodies and act to regulate smooth muscle cell proliferation.	MAPK1 SYNE2	4.61e-06	4	31	2	19861416
Pubmed	Expression patterns of ShcD and Shc family adaptor proteins during mouse embryonic development.	SHC2 SHC3	4.61e-06	4	31	2	21117147
Pubmed	ATF5 Connects the Pericentriolar Materials to the Proximal End of the Mother Centriole.	ATF5 TUBGCP2	4.61e-06	4	31	2	26213385
Pubmed	The ERK1/2-ATG13-FIP200 signaling cascade is required for autophagy induction to protect renal cells from hypoglycemia-induced cell death.	MAPK1 ATG13	4.61e-06	4	31	2	33682133
Pubmed	N-Shc and Sck, two neuronally expressed Shc adapter homologs. Their differential regional expression in the brain and roles in neurotrophin and Src signaling.	SHC2 SHC3	7.68e-06	5	31	2	9507002
Pubmed	Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression.	MAPK1 SHC3	1.15e-05	6	31	2	20442398
Pubmed	Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse.	CTNNBL1 LEF1	1.15e-05	6	31	2	9488439
Pubmed	A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain.	SHC2 SHC3	1.15e-05	6	31	2	8610109
Pubmed	ShcB and ShcC activation by the Trk family of receptor tyrosine kinases.	SHC2 SHC3	1.15e-05	6	31	2	12006576
Pubmed	Insulin-stimulated disassociation of the SOS-Grb2 complex.	SHC2 SHC3	1.15e-05	6	31	2	7739560
Pubmed	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.	CTNNBL1 NAP1L4 PPP4R3B USP13 AARS1 MAPK1 IK	2.50e-05	1014	31	7	32416067
Pubmed	Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2.	TAOK2 MAPK1	2.76e-05	9	31	2	11279118
Pubmed	Hippocampal synaptic modulation by the phosphotyrosine adapter protein ShcC/N-Shc via interaction with the NMDA receptor.	SHC2 SHC3	2.76e-05	9	31	2	15716419
Pubmed	The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons.	SHC2 SHC3	2.76e-05	9	31	2	11163269
Pubmed	Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1.	CTNNBL1 LEF1	2.76e-05	9	31	2	16344550
Pubmed	Gastrin transactivates the chromogranin A gene through MEK-1/ERK- and PKC-dependent phosphorylation of Sp1 and CREB.	PRKD3 MAPK1	3.44e-05	10	31	2	17889508
Pubmed	Ectopic Activation of Fgf8 in Dental Mesenchyme Causes Incisor Agenesis and Molar Microdontia.	MAPK1 LEF1	4.21e-05	11	31	2	39000154
Pubmed	Grit, a GTPase-activating protein for the Rho family, regulates neurite extension through association with the TrkA receptor and N-Shc and CrkL/Crk adapter molecules.	SHC2 SHC3	5.05e-05	12	31	2	12446789
Pubmed	Heparan sulfotransferases Hs6st1 and Hs2st keep Erk in check for mouse corpus callosum development.	MAPK1 LEF1	6.95e-05	14	31	2	24501377
Pubmed	A critical role for miR-142 in alveolar epithelial lineage formation in mouse lung development.	MAPK1 LEF1	6.95e-05	14	31	2	30887098
Pubmed	Genomic organization of the Shc-related phosphotyrosine adapters and characterization of the full-length Sck/ShcB: specific association of p68-Sck/ShcB with pp135.	SHC2 SHC3	6.95e-05	14	31	2	11409899
Pubmed	Wnt/β-catenin signaling in the mouse embryonic cranial mesenchyme is required to sustain the emerging differentiated meningeal layers.	MAPK1 LEF1	6.95e-05	14	31	2	30615824
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	FSIP2 PLEKHA2 AARS1 ATG13 SYNE2 CCSER2	9.81e-05	861	31	6	36931259
Pubmed	Sprouty genes control diastema tooth development via bidirectional antagonism of epithelial-mesenchymal FGF signaling.	MAPK1 LEF1	1.04e-04	17	31	2	16890158
Pubmed	An FGF-WNT gene regulatory network controls lung mesenchyme development.	MAPK1 LEF1	1.04e-04	17	31	2	18533146
Pubmed	An unappreciated role for RNA surveillance.	HFE TUBGCP2 LEF1	1.04e-04	102	31	3	14759258
Pubmed	Lung development requires an active ERK/MAPK pathway in the lung mesenchyme.	MAPK1 LEF1	1.17e-04	18	31	2	27748998
Pubmed	Tissue-specific roles of FGF signaling in external genitalia development.	MAPK1 LEF1	1.17e-04	18	31	2	25820239
Pubmed	Twist1 contributes to cranial bone initiation and dermal condensation by maintaining Wnt signaling responsiveness.	MAPK1 LEF1	1.30e-04	19	31	2	26677825
Pubmed	Inactivation of the 3-phosphoglycerate dehydrogenase gene in mice: changes in gene expression and associated regulatory networks resulting from serine deficiency.	AARS1 ATF5	1.45e-04	20	31	2	18228065
Pubmed	Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway.	PRKD3 MAPK1	1.45e-04	20	31	2	11044099
Pubmed	Function of Wnt/β-catenin in counteracting Tcf3 repression through the Tcf3-β-catenin interaction.	MAPK1 LEF1	1.45e-04	20	31	2	22573616
Pubmed	Molecular characterization of a novel transcription factor that controls stromelysin expression.	THRA LEF1	1.45e-04	20	31	2	7760812
Pubmed	An Alternative Splicing Program for Mouse Craniofacial Development.	LEF1 SYNE2	1.60e-04	21	31	2	33013468
Pubmed	Fgf20 governs formation of primary and secondary dermal condensations in developing hair follicles.	MAPK1 LEF1	1.76e-04	22	31	2	23431057
Pubmed	TCF4 deficiency expands ventral diencephalon signaling and increases induction of pituitary progenitors.	MAPK1 LEF1	1.76e-04	22	31	2	17919533
Pubmed	FAM20B-catalyzed glycosaminoglycans control murine tooth number by restricting FGFR2b signaling.	MAPK1 LEF1	1.76e-04	22	31	2	32664967
Pubmed	Genetic Labeling of Nuclei-Specific Thalamocortical Neurons Reveals Putative Sensory-Modality Specific Genes.	PKNOX2 LEF1	1.92e-04	23	31	2	27655933
Pubmed	MINOS1 is a conserved component of mitofilin complexes and required for mitochondrial function and cristae organization.	MAPK1 TUBGCP2	1.92e-04	23	31	2	22114354
Pubmed	Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones.	CTNNBL1 NAP1L4 AARS1 MAPK1 IK SYNE2 PTCD3	2.02e-04	1415	31	7	28515276
Pubmed	LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells.	NAP1L4 MAPK1 TUBGCP2 PCLO PTCD3	2.36e-04	639	31	5	23443559
Pubmed	DAAM1 and DAAM2 are co-required for myocardial maturation and sarcomere assembly.	MAPK1 LEF1	2.47e-04	26	31	2	26526197
Pubmed	Modeling digits. Digit patterning is controlled by a Bmp-Sox9-Wnt Turing network modulated by morphogen gradients.	MAPK1 LEF1	2.86e-04	28	31	2	25082703
Pubmed	Eda-activated RelB recruits an SWI/SNF (BAF) chromatin-remodeling complex and initiates gene transcription in skin appendage formation.	ATF5 LEF1	2.86e-04	28	31	2	30037996
Pubmed	Dynamic MAPK/ERK Activity Sustains Nephron Progenitors through Niche Regulation and Primes Precursors for Differentiation.	MAPK1 LEF1	3.08e-04	29	31	2	30220628
Pubmed	Transcription factor Foxp3 and its protein partners form a complex regulatory network.	SUGP1 RSBN1 TUBGCP2 IK	3.16e-04	370	31	4	22922362
Pubmed	iRhom2 mutation leads to aberrant hair follicle differentiation in mice.	MAPK1 LEF1	3.29e-04	30	31	2	25546423
Pubmed	Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.	MAPK1 LEF1	3.29e-04	30	31	2	26661618
Pubmed	Lem2 is essential for cardiac development by maintaining nuclear integrity.	MAPK1 SYNE2	3.75e-04	32	31	2	37067297
Pubmed	Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic β-catenin degradation.	MAPK1 LEF1	3.99e-04	33	31	2	33436499
Pubmed	Identification and functional characterization of transcriptional activators in human cells.	AARS1 DNAJC3 PCLO SYNE2	4.16e-04	398	31	4	35016035
Pubmed	Palmitoylation regulates epidermal homeostasis and hair follicle differentiation.	MAPK1 LEF1	4.24e-04	34	31	2	19956733
Pubmed	Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle development.	MAPK1 LEF1	4.24e-04	34	31	2	23123965
Pubmed	Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?	USP13 TUBGCP2 SYNE2	4.66e-04	170	31	3	23314748
Pubmed	Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha.	PRKD3 MAPK1	5.30e-04	38	31	2	12482669
Pubmed	TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia.	PLEKHA2 TUBGCP2	6.17e-04	41	31	2	19786618
Pubmed	An approach based on a genome-wide association study reveals candidate loci for narcolepsy.	MAPK1 IK PCLO	6.74e-04	193	31	3	20677014
Pubmed	Dynamic protein-protein interaction wiring of the human spliceosome.	SUGP1 CTNNBL1 IK	7.16e-04	197	31	3	22365833
Pubmed	ADAM10 hyperactivation acts on piccolo to deplete synaptic vesicle stores in Huntington's disease.	AARS1 MAPK1 PCLO	7.70e-04	202	31	3	33601422
GeneFamily	SH2 domain containing	SHC2 SHC3	4.97e-03	101	19	2	741
Coexpression	GSE17580_TREG_VS_TEFF_DN	PRKD3 NAP1L4 ATF5 LEF1 SYNE2	3.56e-06	200	31	5	M3671
Coexpression	NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_NEGATIVE	RSBN1 SNRK LEF1 ATG13 SYNE2 PTCD3	3.72e-06	363	31	6	M41103
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	PRKD3 NAP1L4 PPP4R3B PLEKHA2 SNRK MAPK1 IK PARVG CCSER2	3.94e-05	1492	31	9	M40023
Coexpression	GSE22886_NAIVE_TCELL_VS_MONOCYTE_UP	LEF1 SYNE2 PTCD3 CCSER2	8.47e-05	198	31	4	M4478
Coexpression	GSE3982_BASOPHIL_VS_TH2_UP	CTNNBL1 IK SHC3 CCSER2	8.81e-05	200	31	4	M5566
Coexpression	GSE37532_WT_VS_PPARG_KO_VISCERAL_ADIPOSE_TISSUE_TREG_DN	CTNNBL1 ATF5 IK DNAJC3	8.81e-05	200	31	4	M8962
Coexpression	GSE17580_TREG_VS_TEFF_S_MANSONI_INF_DN	PRKD3 PPP4R3B LEF1 SYNE2	8.81e-05	200	31	4	M3674
Coexpression	GSE28726_ACT_CD4_TCELL_VS_ACT_VA24NEG_NKTCELL_DN	SNRK LEF1 ATG13 SYNE2	8.81e-05	200	31	4	M8306
Coexpression	GSE24574_BCL6_HIGH_TFH_VS_TFH_CD4_TCELL_DN	SNRK LEF1 ATG13 SYNE2	8.81e-05	200	31	4	M8331
Coexpression	GSE5589_UNSTIM_VS_180MIN_LPS_AND_IL10_STIM_MACROPHAGE_UP	NAP1L4 PPP4R3B PLEKHA2 SYNE2	8.81e-05	200	31	4	M6604
Coexpression	GSE27786_LSK_VS_NKCELL_DN	PLEKHA2 LEF1 DNAJC3 CCSER2	8.81e-05	200	31	4	M4753
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 IKZF5 SYNE2 CCSER2	2.03e-07	191	31	5	696921a4f160b6b55698652488ed781e855e5e51
ToppCell	COPD-Lymphoid-T\|World / Disease state, Lineage and Cell class	NAP1L4 RSBN1 LEF1 SYNE2 CCSER2	2.09e-07	192	31	5	eb4909574fb5fc91399463523e2737095773200a
ToppCell	COPD-Lymphoid-T\|COPD / Disease state, Lineage and Cell class	NAP1L4 RSBN1 LEF1 SYNE2 CCSER2	2.31e-07	196	31	5	30e53b8050d2a041f855d0e39bbd8f923c64c489
ToppCell	mild-CD4+_Tcm\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NAP1L4 RSBN1 LEF1 SYNE2 CCSER2	2.49e-07	199	31	5	06c8a0e39f7a33736548f04a5e2263334c8541cf
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-Treg-Treg_4\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NAP1L4 RSBN1 LEF1 SYNE2	3.77e-06	153	31	4	7518187a5fbf6c0881182dc79bd37c2d49f92b2e
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-Treg-Treg_4\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NAP1L4 RSBN1 LEF1 SYNE2	3.77e-06	153	31	4	93d36723f01c2df39feebf20f3eba5b4fb4cdf59
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2 CCSER2	7.81e-06	184	31	4	bd786db4dc4edae6d5cfc0b69901983dea19f729
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 SNRK LEF1 SYNE2	7.98e-06	185	31	4	847257d232b9993cad50c814fd4ffeef52385295
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-Treg\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	NAP1L4 RSBN1 LEF1 SYNE2	8.51e-06	188	31	4	72be6fe654f3a5f654d3b9680145bce7ae9b721d
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-Treg\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NAP1L4 RSBN1 LEF1 SYNE2	8.51e-06	188	31	4	9db3d3010cb8a1f3ee1cdccaf3cbaac3cf983fc5
ToppCell	COVID-19_Mild-Lymphoid_T/NK-Treg\|COVID-19_Mild / Disease group, lineage and cell class	NAP1L4 RSBN1 LEF1 SYNE2	8.51e-06	188	31	4	42553fdc127e5f613ffd5067620a768a40f1a8a1
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2 CCSER2	8.69e-06	189	31	4	9ab77c6fcb573854da5922412f53d2168bda6b58
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2 CCSER2	8.69e-06	189	31	4	5a9e2ca9a9ee2dc37ab9147a902115a9f1a80169
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_T-T4_em-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	IK LEF1 SYNE2 CCSER2	8.87e-06	190	31	4	f6616b3fe7f4962249503c96c06926240066d861
ToppCell	IPF-Lymphoid-T\|IPF / Disease state, Lineage and Cell class	NAP1L4 LEF1 SYNE2 CCSER2	8.87e-06	190	31	4	d57df208aaf7a5554899bb9107c80b443fd0cf93
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	RSBN1 LEF1 SYNE2 CCSER2	9.05e-06	191	31	4	142f98cabf8737b28369315b3d7a0797ded88e03
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2 CCSER2	9.05e-06	191	31	4	d9a6f61fcda4f5352488f7f55cb9b57aeacc717f
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-Treg\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NAP1L4 RSBN1 LEF1 SYNE2	9.24e-06	192	31	4	7a90ec9fc8f29216c4828e0cf5d040906456e53b
ToppCell	COVID-19_Severe-Lymphoid_T/NK-Treg\|COVID-19_Severe / Disease group, lineage and cell class	NAP1L4 RSBN1 LEF1 SYNE2	9.24e-06	192	31	4	3fb4c148dadcf5e79094e55c6bb53ec7bf9d44c8
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-Treg\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	NAP1L4 RSBN1 LEF1 SYNE2	9.24e-06	192	31	4	d883b91bbab71673de4858346d3ab33e5fbbf842
ToppCell	IPF-Lymphoid-T\|World / Disease state, Lineage and Cell class	NAP1L4 LEF1 SYNE2 CCSER2	9.24e-06	192	31	4	b25ba1f3bc842c22602b2aeed3b1b5082863e4fa
ToppCell	Control-Lymphoid-T\|Control / Disease state, Lineage and Cell class	NAP1L4 LEF1 SYNE2 CCSER2	9.43e-06	193	31	4	af928046ccd1ca874be1534aef6ca7f27d90bc46
ToppCell	nucseq-Immune-Lymphocytic_T/NK-Lymphocytic_T/NK-CD4_T\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NAP1L4 LEF1 SYNE2 CCSER2	9.43e-06	193	31	4	9c9434a3297b85774b4f0ecab6294f44d738e29f
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2 CCSER2	9.63e-06	194	31	4	a44be2f021cfdd0fcdc698c3f04d66db7a1aa6c2
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_T\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2 CCSER2	9.82e-06	195	31	4	53528e5788083bce5a8d4611ab3808878e6a9cd3
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2 CCSER2	9.82e-06	195	31	4	ed5f772c82d4dfd1c8735224446ec9feae3fb8c2
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2 CCSER2	1.00e-05	196	31	4	e4c76e7ad68455e51fe93ce588bcec9383f8654b
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2 CCSER2	1.00e-05	196	31	4	c4e7133c609bcbc48c4947ea0aa1a7d9d7251b04
ToppCell	mild-Treg\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NAP1L4 RSBN1 LEF1 SYNE2	1.02e-05	197	31	4	39800e6e83f2d333b753d121c7aeb2912b91faa2
ToppCell	Sepsis-ICU-SEP-Lymphocyte-T/NK-Treg\|ICU-SEP / Disease, condition lineage and cell class	NAP1L4 FSIP2 LEF1 SYNE2	1.02e-05	197	31	4	c3ee2d522fbfe67069ddba2d1abfc4f5ca230c26
ToppCell	NS-critical-LOC-Lymphoid-CTL\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	NAP1L4 LEF1 SYNE2 CCSER2	1.04e-05	198	31	4	e2acb074142aa62c763139bbcf36f6f85038d04b
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 RSBN1 LEF1 SYNE2	1.04e-05	198	31	4	8a7897d98f5296745d9005a7cd777f0a2f78000d
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	RSBN1 LEF1 SYNE2 CCSER2	1.04e-05	198	31	4	0b9d3518d60d877e1423517fab374381bf678a2b
ToppCell	severe-Treg\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NAP1L4 RSBN1 LEF1 SYNE2	1.04e-05	198	31	4	377980b9f7d02818e1d145e6884604f8bfacc4f2
ToppCell	severe-Treg\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NAP1L4 RSBN1 LEF1 SYNE2	1.04e-05	198	31	4	4935b40fc848037a06055f30d90bde940b9d5321
ToppCell	mild-Treg\|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	NAP1L4 RSBN1 LEF1 SYNE2	1.04e-05	198	31	4	0269617c0628003d2a13dab98abfd2d15775d16a
ToppCell	10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-T_lymphocytic\|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	NAP1L4 LEF1 SYNE2 CCSER2	1.04e-05	198	31	4	db107a5511571384f26e26c6301aef9a9f2423c4
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-T/NK-Treg\|COVID-19_Severe / Disease, condition lineage and cell class	NAP1L4 RSBN1 LEF1 SYNE2	1.09e-05	200	31	4	2b363f2a1d08019b6ff0b10419870049063cc1cf
ToppCell	Control-Control-Lymphocyte-T/NK-dn_T\|Control / Disease, condition lineage and cell class	NAP1L4 LEF1 SYNE2 CCSER2	1.09e-05	200	31	4	10882c59b7aaf8bd4b5c00aa4ddbb9f7ac5b2cf5
ToppCell	COVID-19-COVID-19_Mild-Lymphocyte-T/NK-Treg\|COVID-19_Mild / Disease, condition lineage and cell class	NAP1L4 RSBN1 LEF1 SYNE2	1.09e-05	200	31	4	c6ae15f7deba26008af5b647855675003bb2ebcd
ToppCell	ICU-SEP-Lymphocyte-T_NK-Treg\|ICU-SEP / Disease, Lineage and Cell Type	FSIP2 LEF1 SYNE2	1.38e-04	145	31	3	ee99b58462f955b96d036aa67e343db047d66f64
ToppCell	Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-T_lymphocytic-T_cell\|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	RSBN1 LEF1 SYNE2	1.52e-04	150	31	3	c922dbb4c9c12ccf08bd5f6168b20606c605d052
ToppCell	5'-Adult-Appendix-Hematopoietic-B_cells-Cycling_B_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PRKD3 PLEKHA2 SYNE2	1.71e-04	156	31	3	203ef22eb76bd2b829b027c30af0557080f4006c
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	PRKD3 USP13 SYNE2	1.74e-04	157	31	3	170197b76620df31495f1247f365da382b2d8045
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC-NK_cell\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	PRKD3 USP13 SYNE2	1.74e-04	157	31	3	c21520301cc0d5d4b1cc4b8ec735f9adb698e768
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	PRKD3 USP13 SYNE2	1.78e-04	158	31	3	7274f020c0ecf216da4b6689c62bc5f49c29b6f3
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	LEF1 SYNE2 CCSER2	1.88e-04	161	31	3	5fba13f0aa5002f7eefe219e2c6a07e163f1a50d
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.4.2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	RSBN1 USP13 IK	1.88e-04	161	31	3	1f4614ae15bd2fc08e555cea4d0152c4a940d048
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_T-CD4-positive,_alpha-beta_T_cell-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	LEF1 SYNE2 CCSER2	2.13e-04	168	31	3	5e721268f0baa51d3f640f7f4c41db769ebef210
ToppCell	5'-GW_trimst-2-LargeIntestine-Hematopoietic-T_cells-SELL+_CD8_T\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NAP1L4 PARVG LEF1	2.28e-04	172	31	3	10090b4b40f0f6f07a514e86811cadeecdf21670
ToppCell	Adult-Mesenchymal-pericyte_cell-D175\|Adult / Lineage, Cell type, age group and donor	PKNOX2 ATF5 LEF1	2.32e-04	173	31	3	fd6653d6be9ca6ac36798590694efe03cb758c67
ToppCell	ILEUM-inflamed-(1)_T_(gd)\|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	NAP1L4 MAPK1 LEF1	2.32e-04	173	31	3	85c3e227c81c6ab70148639381389fba3ac5e088
ToppCell	ILEUM-inflamed-(1)_T_cell-(1)_T_(gd)\|(1)_T_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	NAP1L4 MAPK1 LEF1	2.32e-04	173	31	3	62f2f42f54c9c6941bf888956be40230f92c883e
ToppCell	5'-Adult-Distal_Rectal-Epithelial-goblet-Goblet_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	AARS1 SHC2 PTCD3	2.48e-04	177	31	3	e1e45956887371b1c18f1eb479dd930031497520
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma\|TCGA-Brain / Sample_Type by Project: Shred V9	AARS1 THRA CCSER2	2.48e-04	177	31	3	e8ab340b20cd41554c3841fe980e078e878af35f
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	SHC2 LEF1 SYNE2	2.52e-04	178	31	3	73936c2e7e8855b4ab65cad425686513dba331a3
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_T-T4_reg-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2	2.52e-04	178	31	3	90dedb3cef9b01907b9f8eec64218d6d2072be1f
ToppCell	normal-na-Lymphocytic_T-CD4-positive,_alpha-beta_T_cell-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 CCSER2	2.52e-04	178	31	3	fa3585383a1e7da460c88a802aaa81246d681b6b
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_T-T4_reg\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2	2.52e-04	178	31	3	d6312286bf6cc5b107ccd7adb583d9667d4e1d21
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2	2.52e-04	178	31	3	31c847d7f7aa0f6d820afbb45d507992f5e9dc2f
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-Treg-Treg_2\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	RSBN1 LEF1 SYNE2	2.56e-04	179	31	3	593fc323b28304a57ae162f64b0890b893fff446
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-Treg-Treg_2\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	RSBN1 LEF1 SYNE2	2.56e-04	179	31	3	708fc0b8ffcb5fac43c52541acb6671fe1cfbb0d
ToppCell	COVID-19-kidney-PLVAP+EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	SNRK USP13 SYNE2	2.61e-04	180	31	3	493cf8d1a8f2a1ed2672f394a0338b110fd81d88
ToppCell	Control-Lymphoid-T_Regulatory\|Control / Disease state, Lineage and Cell class	NAP1L4 LEF1 SYNE2	2.69e-04	182	31	3	31bb838cc2900f3c9da9f835d79d557a08abb928
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	PPP4R3B LEF1 SYNE2	2.69e-04	182	31	3	b427e43ee523a3ea9eca3207f3d82042f10f022a
ToppCell	facs-Heart-LV-18m-Lymphocytic\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PLEKHA2 PARVG LEF1	2.69e-04	182	31	3	d0d18dd5d8b2d21e42c3c4259f824c91f24a54bc
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	PPP4R3B LEF1 SYNE2	2.69e-04	182	31	3	1aea96ee211f7b9caef7fd385233f51be6021a73
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	PPP4R3B LEF1 SYNE2	2.69e-04	182	31	3	c0f63cfc67d61c0877b7acb2946dfb35aae8a8f5
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	PPP4R3B LEF1 SYNE2	2.69e-04	182	31	3	4cb182ef39be2044a6ad7266f332d4177591e550
ToppCell	COVID-19_Mild-Lymphoid_T/NK-CD4+_T_activated\|COVID-19_Mild / Disease group, lineage and cell class	PPP4R3B LEF1 SYNE2	2.74e-04	183	31	3	7717fce227b4e02ed41baad8ae7dd2e22bd7c13e
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD4-positive,_alpha-beta_memory_T_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	NAP1L4 RSBN1 LEF1	2.74e-04	183	31	3	aa66149363bb0b6fe1b6044aa2001ace0e4f717e
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c02-AQP3\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	RSBN1 LEF1 SYNE2	2.74e-04	183	31	3	317b756378a9efd8ecb754acf7273f83f996e106
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2	2.74e-04	183	31	3	f2ef110bf29b1a8276ef216238363e542db262c1
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	THRA LEF1 IKZF5	2.78e-04	184	31	3	a6dee97ee4ef9d89e11d17339e0dadaea1210ce5
ToppCell	normal-na-Lymphocytic_T-T8_naive-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 CCSER2	2.78e-04	184	31	3	4a81190b36d197736663e6177d3b76c1cb6282d6
ToppCell	COVID-19_Severe-gd_T\|COVID-19_Severe / Disease condition and Cell class	PPP4R3B MAPK1 SYNE2	2.78e-04	184	31	3	791f1bcb954aadc63d4117c400537d036f68734d
ToppCell	Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-T_lymphocytic\|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	IK LEF1 SYNE2	2.82e-04	185	31	3	115a74d0b9be580005d45d22d6e228801b2705e2
ToppCell	Fetal_29-31_weeks-Mesenchymal-pericyte_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PKNOX2 PLEKHA2 LEF1	2.82e-04	185	31	3	a7dba7db79275884b2a93d8a16f2e0c739e71370
ToppCell	IPF-Lymphoid-T_Regulatory\|IPF / Disease state, Lineage and Cell class	NAP1L4 LEF1 SYNE2	2.82e-04	185	31	3	221cbd09d94cc0947d0e3c1aa14716d17cb2068d
ToppCell	IPF-Lymphoid-T_Regulatory\|World / Disease state, Lineage and Cell class	NAP1L4 LEF1 SYNE2	2.82e-04	185	31	3	77fbecdab10bacc005b1c7e22ca414cfecef13c1
ToppCell	Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-T_lymphocytic-effector_CD4-positive,_alpha-beta_T_cell\|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	LEF1 SYNE2 CCSER2	2.92e-04	187	31	3	e61c1755531469dd3850c9740474b5ad4e0499c1
ToppCell	Fetal_29-31_weeks-Mesenchymal-pericyte_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PKNOX2 PLEKHA2 LEF1	2.92e-04	187	31	3	a2bf958ea59c359a265bfa437d59315e1920cdd4
ToppCell	3'_v3-Lung-Lymphocytic_T_CD4-Tregs\|Lung / Manually curated celltypes from each tissue	RSBN1 LEF1 SYNE2	2.96e-04	188	31	3	604f340052807bd902915eca942a97ccc36b42e0
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_T-T4_reg\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2	2.96e-04	188	31	3	e5c480b9a030536578f1cc91fb61738f752525b3
ToppCell	(1)_T_CD4_reg\|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)	NAP1L4 LEF1 SYNE2	3.01e-04	189	31	3	28f28672fd260bb2a8d64152737a7242347c3174
ToppCell	10x_3'_v3-spleen_(10x_3'_v3)-lymphocytic-T_lymphocytic-regulatory_T_cell\|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	NAP1L4 LEF1 SYNE2	3.01e-04	189	31	3	9f6f6fe6e47f5c5fd48aab47a775f7bdd16de19c
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c06-NR4A2\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NAP1L4 LEF1 SYNE2	3.01e-04	189	31	3	8130102c41b2978a8b83f765ce383f836a464795
ToppCell	normal_Pleural_Fluid-T/NK_cells-Treg\|normal_Pleural_Fluid / Location, Cell class and cell subclass	RSBN1 LEF1 SYNE2	3.05e-04	190	31	3	632b9541371483d25948b6f033863c49f38e3603
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_T-T4_em\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2	3.05e-04	190	31	3	1634a6044dce4e026a63976031a498c7460e3dce
ToppCell	normal-na-Lymphocytic_T-T4_reg\|normal / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2	3.05e-04	190	31	3	b8897c3e0fe8bb7efaf6a3787104d454d81a4c92
ToppCell	normal-na-Lymphocytic_T-T4_reg-female\|normal / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2	3.05e-04	190	31	3	d8c1998eb02d5105598608d4733b63978ffa3eb2
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_T-T4_em-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2	3.05e-04	190	31	3	08813c2f9321b82f0ec66854bb7a383aa1171780
ToppCell	10x_3'_v3-lymph_node_(10x_3'_v3)-lymphocytic-T_lymphocytic-regulatory_T_cell\|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	NAP1L4 LEF1 SYNE2	3.05e-04	190	31	3	b69709323a9f1b368b5a4f87295b9f7fd9c9be8e
ToppCell	Control-Plasmablast\|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)	AARS1 ATF5 DNAJC3	3.10e-04	191	31	3	3df5bbdb29bbcbcb8476fdf126b6d4c1ac67d64b
ToppCell	(1)_T_CD4_fh\|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)	NAP1L4 LEF1 SYNE2	3.10e-04	191	31	3	66ddff9a99092cb384b9fb2a3ba95ddbebed67cc
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_T-T4_reg-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	NAP1L4 LEF1 SYNE2	3.10e-04	191	31	3	c5e22df4a8741b8096cdd1618271fd48d6265846
ToppCell	10x_3'_v3-lymph_node_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD4-positive,_alpha-beta_memory_T_cell\|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	LEF1 SYNE2 CCSER2	3.10e-04	191	31	3	e0e87cba486608e569f257e95cde2ca8472fc3dd
ToppCell	COVID-19-T_cells-CD4+_T_cells\|COVID-19 / group, cell type (main and fine annotations)	LEF1 SYNE2 CCSER2	3.10e-04	191	31	3	0646cca78e24aeb6baa9934d3c439b797c567997
ToppCell	COVID-19-T_cells\|COVID-19 / group, cell type (main and fine annotations)	LEF1 SYNE2 CCSER2	3.10e-04	191	31	3	7f64add931b64b8d35836fa6bee9ebab593844d3
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_T-T4_em\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	LEF1 SYNE2 CCSER2	3.15e-04	192	31	3	e07b6892276c81c1227e94ca942f6820d89a7ca3
Drug	clotrimazole; Up 200; 50uM; MCF7; HT_HG-U133A_EA	SUGP1 PRKD3 HFE PPP4R3B ATG13	4.80e-06	185	31	5	905_UP
Drug	Fenoprofen calcium salt dihydrate [53746-45-5]; Down 200; 7.2uM; MCF7; HT_HG-U133A	HFE PLEKHA2 TUBGCP2 PCLO IKZF5	6.05e-06	194	31	5	4736_DN
Drug	Norgestrel-(-)-D [797-63-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A	SUGP1 PRKD3 HFE PLEKHA2 TUBGCP2	6.05e-06	194	31	5	3606_DN
Drug	Acacetin [480-44-4]; Down 200; 14uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 PLEKHA2 SNRK PCLO	6.36e-06	196	31	5	3849_DN
Drug	Allantoin [97-59-6]; Up 200; 25.2uM; PC3; HT_HG-U133A	MAPK1 TUBGCP2 DNAJC3 PCLO IKZF5	6.52e-06	197	31	5	1800_UP
Drug	tamoxifen citrate; Up 200; 1uM; MCF7; HG-U133A	TAOK2 NAP1L4 HFE DNAJC3 SYNE2	6.85e-06	199	31	5	143_UP
Drug	2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A	SUGP1 PRKD3 HFE PPP4R3B ATG13	6.85e-06	199	31	5	6969_DN
Drug	L-T3-PAL	CTNNBL1 THRA	3.75e-05	7	31	2	CID005487638
Drug	ioxynil	MAPK1 THRA	5.00e-05	8	31	2	ctd:C008161
Drug	2-aminotetralin-2-carboxylic acid	CTNNBL1 HFE	6.42e-05	9	31	2	CID000235533
Drug	Thiram	PKNOX2 PPP4R3B MAPK1 LEF1 IKZF5 SYNE2	7.16e-05	533	31	6	ctd:D013893
Drug	17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA	SUGP1 HFE PPP4R3B ATG13	9.64e-05	178	31	4	916_UP
Drug	Butylated Hydroxytoluene	PKNOX2 MAPK1 LEF1 DNAJC3	9.64e-05	178	31	4	ctd:D002084
Drug	Metoclopramide monohydrochloride [7232-21-5]; Down 200; 11.8uM; HL60; HT_HG-U133A	SUGP1 PLEKHA2 MAPK1 TUBGCP2	1.14e-04	186	31	4	2353_DN
Drug	Promazine hydrochloride [53-60-1]; Down 200; 12.4uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 PRKD3 MAPK1	1.24e-04	190	31	4	3833_DN
Drug	Dorzolamide hydrochloride [130693-82-2]; Down 200; 11uM; HL60; HT_HG-U133A	SUGP1 PLEKHA2 MAPK1 ATG13	1.26e-04	191	31	4	6142_DN
Drug	Fenbendazole [43210-67-9]; Down 200; 13.4uM; MCF7; HT_HG-U133A	SUGP1 PRKD3 HFE PLEKHA2	1.26e-04	191	31	4	3888_DN
Drug	Meclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; PC3; HT_HG-U133A	PLEKHA2 DNAJC3 PCLO IKZF5	1.29e-04	192	31	4	4268_DN
Drug	Fusaric acid [536-69-6]; Down 200; 22.4uM; MCF7; HT_HG-U133A	MAPK1 TUBGCP2 ATG13 IKZF5	1.29e-04	192	31	4	3245_DN
Drug	Cyanocobalamin [68-19-9]; Down 200; 3uM; MCF7; HT_HG-U133A	HFE PPP4R3B TUBGCP2 DNAJC3	1.29e-04	192	31	4	3252_DN
Drug	Bisacodyl [603-50-9]; Down 200; 11uM; PC3; HT_HG-U133A	TAOK2 SUGP1 PPP4R3B CCSER2	1.32e-04	193	31	4	4616_DN
Drug	Boldine [476-70-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A	SUGP1 PRKD3 PLEKHA2 ATG13	1.32e-04	193	31	4	4122_UP
Drug	Fludrocortisone acetate [514-36-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE SNRK	1.32e-04	193	31	4	3866_DN
Drug	rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA	SUGP1 PRKD3 HFE ATG13	1.32e-04	193	31	4	921_UP
Drug	Rapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A	TAOK2 SUGP1 PPP4R3B ATF5	1.34e-04	194	31	4	6201_DN
Drug	Corticosterone [50-22-6]; Down 200; 11.6uM; HL60; HT_HG-U133A	TAOK2 SUGP1 PPP4R3B CCSER2	1.34e-04	194	31	4	1307_DN
Drug	Methionine sulfoximine (L) [15985-39-4]; Down 200; 22.2uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE PLEKHA2	1.34e-04	194	31	4	2831_DN
Drug	butein; Down 200; 10uM; PC3; HG-U133A	SUGP1 HFE TUBGCP2 CCSER2	1.34e-04	194	31	4	582_DN
Drug	Scopolamine hydrochloride [55-16-3]; Down 200; 11.8uM; PC3; HT_HG-U133A	SUGP1 PPP4R3B TUBGCP2 LEF1	1.34e-04	194	31	4	4219_DN
Drug	Chlorthalidone [77-36-1]; Down 200; 11.8uM; HL60; HG-U133A	SUGP1 PRKD3 SNRK DNAJC3	1.34e-04	194	31	4	1581_DN
Drug	Proglumide [6620-60-6]; Down 200; 12uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE SNRK	1.34e-04	194	31	4	3861_DN
Drug	Haloperidol [52-86-8]; Down 200; 10.6uM; PC3; HT_HG-U133A	TAOK2 SUGP1 PPP4R3B TUBGCP2	1.34e-04	194	31	4	4678_DN
Drug	Ethamivan [304-84-7]; Down 200; 18uM; PC3; HT_HG-U133A	SUGP1 PLEKHA2 ATG13 CCSER2	1.34e-04	194	31	4	7260_DN
Drug	Indoprofen [31842-01-0]; Up 200; 14.2uM; MCF7; HT_HG-U133A	SUGP1 HFE PLEKHA2 TUBGCP2	1.34e-04	194	31	4	3345_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A	TAOK2 SUGP1 PPP4R3B THRA	1.34e-04	194	31	4	2474_DN
Drug	Dinoprost trometamol [38362-01-5]; Up 200; 8.4uM; PC3; HT_HG-U133A	SUGP1 SNRK TUBGCP2 LEF1	1.34e-04	194	31	4	6308_UP
Drug	Ivermectin [70288-86-7]; Down 200; 4.6uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE ATF5	1.34e-04	194	31	4	2213_DN
Drug	5186324; Up 200; 2uM; MCF7; HT_HG-U133A_EA	SUGP1 HFE PPP4R3B THRA	1.37e-04	195	31	4	900_UP
Drug	2-propylpentanoic acid; Down 200; 50uM; HL60; HT_HG-U133A	SUGP1 PPP4R3B SNRK CCSER2	1.37e-04	195	31	4	1163_DN
Drug	ICI182,780; Up 200; 1uM; PC3; HT_HG-U133A	SUGP1 PRKD3 ATF5 PCLO	1.37e-04	195	31	4	6918_UP
Drug	alpha-estradiol; Up 200; 0.01uM; PC3; HT_HG-U133A	TAOK2 PKNOX2 HFE SHC2	1.37e-04	195	31	4	4434_UP
Drug	(d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; HL60; HT_HG-U133A	TAOK2 SUGP1 HFE CCSER2	1.37e-04	195	31	4	2163_DN
Drug	Ethionamide [536-33-4]; Down 200; 24uM; MCF7; HT_HG-U133A	SUGP1 PKNOX2 HFE PCLO	1.37e-04	195	31	4	4418_DN
Drug	Spectinomycin dihydrochloride [21736-83-4]; Up 200; 9.8uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE TUBGCP2	1.37e-04	195	31	4	3327_UP
Drug	Amoxicillin [26787-78-0]; Up 200; 11uM; MCF7; HT_HG-U133A	TAOK2 PKNOX2 HFE PCLO	1.37e-04	195	31	4	5385_UP
Drug	Tranylcypromine hydrochloride [1986-47-6]; Down 200; 23.6uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 PRKD3 TUBGCP2	1.37e-04	195	31	4	2264_DN
Drug	Chicago sky blue 6B [2610-05-1]; Up 200; 4uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 PRKD3 PLEKHA2	1.37e-04	195	31	4	3266_UP
Drug	Clofazimine [2030-63-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A	SUGP1 HFE PLEKHA2 PCLO	1.37e-04	195	31	4	5277_DN
Drug	carbamazepine; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA	SUGP1 PRKD3 HFE PPP4R3B	1.37e-04	195	31	4	919_UP
Drug	Pancuronium bromide [15500-66-0]; Down 200; 5.4uM; MCF7; HT_HG-U133A	SUGP1 PLEKHA2 PCLO SYNE2	1.37e-04	195	31	4	4393_DN
Drug	Baclofen (R,S) [1134-47-0]; Up 200; 18.8uM; PC3; HT_HG-U133A	SUGP1 HFE SNRK MAPK1	1.40e-04	196	31	4	6313_UP
Drug	Carisoprodol [78-44-4]; Down 200; 15.4uM; PC3; HT_HG-U133A	PLEKHA2 SNRK DNAJC3 IKZF5	1.40e-04	196	31	4	6610_DN
Drug	Troleandomycin [2751-09-9]; Down 200; 5uM; MCF7; HT_HG-U133A	SUGP1 HFE MAPK1 DNAJC3	1.40e-04	196	31	4	1465_DN
Drug	Aztreonam [78110-38-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A	TAOK2 PKNOX2 HFE PLEKHA2	1.40e-04	196	31	4	2282_UP
Drug	Glafenine hydrochloride [65513-72-6]; Down 200; 9.8uM; PC3; HT_HG-U133A	SUGP1 CTNNBL1 ATG13 CCSER2	1.40e-04	196	31	4	7257_DN
Drug	2-propylpentanoic acid; Up 200; 500uM; MCF7; HT_HG-U133A_EA	SUGP1 HFE PPP4R3B ATG13	1.40e-04	196	31	4	1078_UP
Drug	Orlistat; Up 200; 10uM; PC3; HT_HG-U133A	SNRK THRA TUBGCP2 IKZF5	1.40e-04	196	31	4	6420_UP
Drug	Metyrapone [54-36-4]; Down 200; 17.6uM; MCF7; HT_HG-U133A	SUGP1 PRKD3 MAPK1 TUBGCP2	1.40e-04	196	31	4	6447_DN
Drug	Hydroflumethiazide [135-09-1]; Down 200; 12uM; HL60; HT_HG-U133A	PRKD3 TUBGCP2 DNAJC3 IKZF5	1.40e-04	196	31	4	1851_DN
Drug	Doxycycline hydrochloride [10592-13-9]; Down 200; 8.4uM; HL60; HT_HG-U133A	SUGP1 HFE PPP4R3B CCSER2	1.40e-04	196	31	4	2737_DN
Drug	Fluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A	HFE TUBGCP2 ATG13 CCSER2	1.40e-04	196	31	4	5290_DN
Drug	Amprolium hydrochloride [137-88-2]; Up 200; 12.6uM; MCF7; HT_HG-U133A	TAOK2 TUBGCP2 SHC2 PCLO	1.40e-04	196	31	4	4825_UP
Drug	Triflupromazine hydrochloride [1098-60-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 SNRK CCSER2	1.40e-04	196	31	4	1691_DN
Drug	(-)-depudecin; Down 200; 1uM; MCF7; HT_HG-U133A_EA	SUGP1 PPP4R3B MAPK1 CCSER2	1.40e-04	196	31	4	874_DN
Drug	Sulpiride [15676-16-1]; Up 200; 11.8uM; HL60; HG-U133A	SUGP1 HFE DNAJC3 ATG13	1.40e-04	196	31	4	1967_UP
Drug	Clioquinol [130-26-7]; Down 200; 13uM; PC3; HT_HG-U133A	TAOK2 SUGP1 PPP4R3B THRA	1.40e-04	196	31	4	4663_DN
Drug	Isosorbide dinitrate [87-33-2]; Down 200; 17uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE CCSER2	1.40e-04	196	31	4	6038_DN
Drug	Methazolamide [554-57-4]; Down 200; 17uM; HL60; HT_HG-U133A	CTNNBL1 PPP4R3B IKZF5 CCSER2	1.40e-04	196	31	4	2733_DN
Drug	Bemegride [64-65-3]; Down 200; 25.8uM; MCF7; HT_HG-U133A	SUGP1 PKNOX2 PLEKHA2 TUBGCP2	1.40e-04	196	31	4	3389_DN
Drug	Josamycin [16846-24-5]; Up 200; 4.8uM; PC3; HT_HG-U133A	TAOK2 SNRK TUBGCP2 LEF1	1.42e-04	197	31	4	4631_UP
Drug	Gelsemine [509-15-9]; Up 200; 12.4uM; PC3; HT_HG-U133A	TAOK2 SUGP1 PKNOX2 HFE	1.42e-04	197	31	4	4097_UP
Drug	Isoconazole [27523-40-6]; Down 200; 9.6uM; MCF7; HT_HG-U133A	SUGP1 HFE ATF5 THRA	1.42e-04	197	31	4	2218_DN
Drug	Benfotiamine [22457-89-2]; Down 200; 8.6uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE SNRK	1.42e-04	197	31	4	3837_DN
Drug	clozapine; Up 200; 10uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE PLEKHA2	1.42e-04	197	31	4	6988_UP
Drug	Meprylcaine hydrochloride [956-03-6]; Up 200; 14.8uM; MCF7; HT_HG-U133A	SUGP1 PRKD3 PKNOX2 SHC2	1.42e-04	197	31	4	6204_UP
Drug	Benperidol [2062-84-2]; Up 200; 10.4uM; HL60; HT_HG-U133A	TAOK2 PKNOX2 HFE CCSER2	1.42e-04	197	31	4	2475_UP
Drug	CP-319743 [172078-87-4]; Up 200; 10uM; PC3; HT_HG-U133A	SUGP1 TUBGCP2 DNAJC3 IKZF5	1.42e-04	197	31	4	7491_UP
Drug	Vidarabine [5536-17-4]; Up 200; 15uM; PC3; HT_HG-U133A	SUGP1 PKNOX2 HFE IKZF5	1.42e-04	197	31	4	5850_UP
Drug	Amitryptiline hydrochloride [549-18-8]; Down 200; 12.8uM; MCF7; HT_HG-U133A	SUGP1 PRKD3 HFE PCLO	1.42e-04	197	31	4	5453_DN
Drug	Cloperastine hydrochloride [14984-68-0]; Down 200; 11uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 HFE THRA	1.42e-04	197	31	4	4732_DN
Drug	Fluoxetine hydrochloride [59333-67-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 PRKD3 TUBGCP2	1.42e-04	197	31	4	5356_DN
Drug	Sulconazole nitrate [61318-91-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A	SUGP1 PPP4R3B MAPK1 TUBGCP2	1.42e-04	197	31	4	4998_DN
Drug	Prednisone [53-03-2]; Down 200; 11.2uM; PC3; HT_HG-U133A	SUGP1 MAPK1 THRA ATG13	1.42e-04	197	31	4	4577_DN
Drug	D-cycloserine [68-41-7]; Down 200; 39.2uM; HL60; HT_HG-U133A	SUGP1 HFE SNRK CCSER2	1.42e-04	197	31	4	6139_DN
Drug	Minoxidil [38304-91-5]; Down 200; 19.2uM; PC3; HT_HG-U133A	PPP4R3B MAPK1 IKZF5 CCSER2	1.42e-04	197	31	4	4216_DN
Drug	Ifenprodil tartrate [23210-58-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	SUGP1 HFE TUBGCP2 ATG13	1.42e-04	197	31	4	5463_DN
Drug	Xylazine [7361-61-7]; Down 200; 18.2uM; MCF7; HT_HG-U133A	SUGP1 PRKD3 HFE TUBGCP2	1.42e-04	197	31	4	2788_DN
Drug	Tiletamine hydrochloride; Up 200; 15.4uM; MCF7; HT_HG-U133A	SUGP1 THRA SHC2 PCLO	1.45e-04	198	31	4	6013_UP
Drug	Nadide [53-84-9]; Down 200; 6uM; HL60; HT_HG-U133A	SUGP1 PPP4R3B THRA TUBGCP2	1.45e-04	198	31	4	2529_DN
Drug	Sulfamethazine sodium salt [1981-58-4]; Down 200; 13.4uM; HL60; HT_HG-U133A	TAOK2 SUGP1 THRA TUBGCP2	1.45e-04	198	31	4	2560_DN
Drug	estradiol, USP; Down 200; 0.1uM; MCF7; HT_HG-U133A	TAOK2 SUGP1 MAPK1 IKZF5	1.45e-04	198	31	4	1633_DN
Drug	PHA-00816795 [212631-79-3]; Down 200; 10uM; PC3; HT_HG-U133A	SUGP1 PLEKHA2 DNAJC3 ATG13	1.45e-04	198	31	4	7076_DN
Drug	Benzathine benzylpenicillin [5928-84-7]; Down 200; 4.2uM; MCF7; HT_HG-U133A	PRKD3 HFE PPP4R3B ATG13	1.45e-04	198	31	4	7359_DN
Drug	Trichlormethiazide [133-67-5]; Up 200; 10.6uM; MCF7; HT_HG-U133A	SUGP1 PKNOX2 HFE IKZF5	1.45e-04	198	31	4	4783_UP
Drug	Isocorydine (+) [475-67-2]; Up 200; 11.8uM; PC3; HT_HG-U133A	TAOK2 SUGP1 HFE SHC2	1.45e-04	198	31	4	4505_UP
Drug	Ketoprofen [22071-15-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A	TAOK2 HFE PLEKHA2 THRA	1.45e-04	198	31	4	3626_DN
Drug	Methocarbamol [532-03-6]; Up 200; 16.6uM; PC3; HT_HG-U133A	SUGP1 PLEKHA2 MAPK1 ATG13	1.45e-04	198	31	4	2111_UP
Drug	Avermectin B1 [71751-41-2]; Down 200; 4.8uM; PC3; HT_HG-U133A	TAOK2 SUGP1 SNRK SYNE2	1.45e-04	198	31	4	5864_DN
Drug	Isoxsuprine hydrochloride [579-56-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A	SUGP1 HFE MAPK1 IKZF5	1.45e-04	198	31	4	4789_UP
Drug	Amoxapine [14028-44-5]; Up 200; 12.8uM; HL60; HG-U133A	TAOK2 HFE PLEKHA2 SNRK	1.45e-04	198	31	4	2013_UP
Disease	superior parietal cortex volume measurement	MAPK1 SHC3	1.11e-04	15	31	2	EFO_0010330
Disease	osteoarthritis, knee, body mass index	TAOK2 AARS1	8.54e-04	41	31	2	EFO_0004340, EFO_0004616
Disease	triglycerides in large LDL measurement	SUGP1 SYNE2	9.39e-04	43	31	2	EFO_0022319
Disease	triglycerides in LDL measurement	SUGP1 SYNE2	1.59e-03	56	31	2	EFO_0022320
Disease	ovarian cancer (is_implicated_in)	HFE LEF1	1.59e-03	56	31	2	DOID:2394 (is_implicated_in)
Disease	renal cell carcinoma (is_implicated_in)	MAPK1 THRA	2.40e-03	69	31	2	DOID:4450 (is_implicated_in)
Disease	bipolar disorder	TAOK2 MAPK1 THRA PCLO	2.99e-03	577	31	4	MONDO_0004985
Disease	hypothyroidism	HFE PPP4R3B RSBN1	3.25e-03	284	31	3	EFO_0004705

Protein segments in the cluster

Peptide	Gene	Start	Entry
MIDFKPAFSKDDILP	ATG13	446	O75143
IKFPDNPEKFMESEL	CTNNBL1	101	Q8WYA6
DDEEPKKVDILLFPM	CFAP92	126	Q9ULG3
DPEMRKKFDDGEDPL	DNAJC3	451	Q13217
KKELEQMEDFFLDAP	ATF5	106	Q9Y2D1
DEPPKDVFDELFKLA	PARVG	191	Q9HBI0
DEMIPFKDEGDPQKE	LEF1	21	Q9UJU2
DEPIAEAPFKFDMEL	MAPK1	321	P28482
EAPFKFDMELDDLPK	MAPK1	326	P28482
KMKSEPDKADPFSFE	NAP1L4	226	Q99733
MGKRFSPKDPDDDKF	PTCD3	401	Q96EY7
SPKDPDDDKFFQSAM	PTCD3	406	Q96EY7
ENELKEKKFPPDDEF	FSIP2	5136	Q5CZC0
EEDPMEDPYELKLLK	PCLO	4111	Q9Y6V0
PEDKMFFLDPSDLDV	PRKD3	366	O94806
TDPFKDDLKIDLMPH	TUBGCP2	566	Q9BSJ2
MDAKEFEPKDVLPNG	HFE	246	Q30201
KPEDDFPDNYEKFME	PPP4R3B	736	Q5MIZ7
MGEKKPEPLDFVKDF	IKZF5	1	Q9H5V7
PQDMFDSPKENEKAF	CCSER2	446	Q9H7U1
KPFFSDDPELDNLMV	PKNOX2	121	Q96KN3
FPEFLDMLEESPFLK	RSBN1	491	Q5VWQ0
PKEKPFMFNLDDENI	PLEKHA2	406	Q9HB19
NKMKTFEEPPFEKEA	SYNE2	1606	Q8WXH0
PRKDLFDMKPFEDAL	SHC3	446	Q92529
KDPDVAELFFKDDPE	TAOK2	11	Q9UL54
DDEFDMDENLPPKLS	SNRK	496	Q9NRH2
GDFLPPDELEKFMET	SUGP1	526	Q8IWZ8
SLGDAFPELKKDPDM	AARS1	356	P49588
EDSPKKDLFDMRPFE	SHC2	426	P98077
LEEKKPPEADMNIFE	IK	306	Q13123
DFAKKLPMFSELPCE	THRA	231	P10827
PKKFDVSIDMPDLLD	USP13	596	Q92995